A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT02166814
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 140 participants
- Registry
-
NCT02166814
-
- Other papers using this trial's data
- The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02166814. Randomized; triple masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
- Condition
- Essential Hypertension, Dyslipidemia
- Intervention (Drug)
- Fimasartan and Rosuvastatin
- Intervention (Drug)
- Fimasartan
- Intervention (Drug)
- Rosuvastatin
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct02166814- Content hash
6066152431ded0bed577f9774dbbaa4ba3c1d81e55de2844f2c99211aaed82d4